GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Liabilities-to-Assets

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Liabilities-to-Assets : 0.70 (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. GlaxoSmithKline Consumer Nigeria's Total Liabilities for the quarter that ended in Jun. 2023 was ₦21,054 Mil. GlaxoSmithKline Consumer Nigeria's Total Assets for the quarter that ended in Jun. 2023 was ₦30,268 Mil. Therefore, GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 0.70.


GlaxoSmithKline Consumer Nigeria Liabilities-to-Assets Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Liabilities-to-Assets Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.51 0.62 0.65 0.68

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.66 0.68 0.68 0.70

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets falls into.



GlaxoSmithKline Consumer Nigeria Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=19853.752/29386.204
=0.68

GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as

Liabilities-to-Assets (Q: Jun. 2023 )=Total Liabilities/Total Assets
=21053.574/30268.016
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


GlaxoSmithKline Consumer Nigeria Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines